

### **PATENT**

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE (Case No. 01-1554-F)

In the Appl	ication of:	)
	Varnum et al.	Before the Examiner:
Serial No.	10/656,769	)
Filed:	September 5, 2003	) Group Art Unit: 1640 )
For:	Therapeutic Human Anti-IL-1R1	) Confirmation No.: 8860
	Monoclonal Antibody	)

Mail Stop Amendment Commissioner for Patents Alexandria, VA 22313-1450

### INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. Section 1.97 - 1.99, the Applicant wishes to make the following references of record in the above-identified application. This Supplemental Information Disclosure Statement is in compliance with the continuing duty of candor as set forth in 37 C.F.R. Section 1.56. These references are listed on the enclosed PTO Form 1449.

In the judgment of the undersigned, portions of the listed references may be material to the Examiner's consideration of the presently pending claims. This statement is not a representation that the listed references have effective dates early enough to be "prior art" within the meaning of 35 U.S.C. Section 102 or Section 103.

Please charge any fee that is due with this submission to Deposit Account 13-2490.

Respectfully submitted,

McDonnell Boehnen Hulbert & Berghoff LLP

Date: April 11, 2006

Reg. No. 50,69

FORM PTO-1449 (Rev. 2-32)
APR 1 4 2006
TO TO A DOCUMENT

# U.S. Department of Commerce Patent and Trademark Office

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

Atty.	Docket	No.
-------	--------	-----

# 01-1554-F

# 10/656,769

Serial No.

Applicant:

Brian Varnum, et al

Filing Date:

Group:

# September 5, 2003

# N/A

#### **U.S. PATENT DOCUMENTS**

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
	1.	6,248,516	06/19/2001	Winter, et al			
	2.	5,081,228	January 14, 1992	Dower, et al.			
	3.	4,968,607	November 6, 1990	Dower, et al.			
	4.	5,180,812	January 19, 1993	Dower, et al.			
	5.	5,319,071	June 7, 1994	Dower, et al.			
	6.	5,492,888	February 20, 1996	Dower, et al.			
	7.	5,296,592	March 22, 1994	Dower, et al.			
	8.	6,511,665	January 28, 2003	Dower, et al.			
	9.	5,488,032	January 30, 1996	Dower, et al.			

#### FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Transl	ation
10.	EP623674	November 24, 1988	Europe				No

EXAMINER	DATE CONSIDERED	

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

11.	Barbas et al., "Human autoantibody recognition of DNA", Proc Natl Acad Sci U S A. 1995 Mar 28;92(7):2529-33
12.	Beiboer et al., "Guided selection of a pan carcinoma specific antibody reveals similar binding characteristics yet structural divergence between the original murine antibody and its human equivalent", J Mol Biol. 2000 Feb 25;296(3):833-49.
13.	Desiderio A et al., "A semi-synthetic Repertoire of Intrinsically Stable Antibody Fragments Derived from a Single-framework Scaffold", <i>J. Mol. Biol.</i> 2001; 310, 603-615
14.	Desmyter A, et al., "Antigen Specificity and High Affinity Binding Provided by One Single Loop of a Camel Single-domain Antibody", The Journal of Biological Chemistry 2001; Vol. 276, No. 28, pp. 26285-26290
15.	Ditzel et al., "Determinants of polyreactivity in a large panel of recombinant human antibodies from HIV-1 infection", J Immunol. 1996 Jul 15;157(2):739-49
16.	Klimka et al., "Human anti-CD30 recombinant antibodies by guided phage antibody selection using cell panning", Br J Cancer. 2000 Jul;83(2):252-60
17.	Rader et al., "A phage display approach for rapid antibody humanization: designed combinatorial V gene libraries", Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8910-5
18.	Schier R, et al., "Isolation of Picomolar Affinity Anti-c-erbB-2 Single-Chain Fv by Molecular Evolution of the Complementarity Determing Regions in the Center of the Antibody Binding Site", <i>J. Mol. Biol.</i> 1996; 263, 551-567

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.